Sanofi: US FDA accepts for priority review Sanofi's regulatory submission of tolebrutinib for patients with multiple sclerosis

The US Food and Drug Administration (FDA) is evaluating under priority review the regulatory submission of tolebrutinib to treat non─relapsing secondary progressive multiple sclerosis (nrSPMS) and to slow disability